Choose Your Country or Region

Creatinine

Catalog No.S3102 Purity:99.90%

research use only

Creatinine(NSC13123) is a break-down product of creatine phosphate in muscle, and is usually produced at a fairly constant rate by the body.

Creatinine Chemical Structure

Molecular Weight: 113.12

Purity & Quality Control

Batch: S310201 Water]23 mg/mL]false]DMSO]Insoluble]false]Ethanol]Insoluble]false Purity: 99.90%

99.90

Creatinine Related Products

Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole NAD+ 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Pitstop 2 Sesamin Bilobalide Formononetin Hesperidin Azeliragon (TTP488) L-Mimosine Ademetionine	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Express-Pick Library	Click to Expand

Mechanism of Action

Description	Creatinine(NSC13123) is a break-down product of creatine phosphate in muscle, and is usually produced at a fairly constant rate by the body.

In vitro
In vitro	Creatinine is a break-down product of creatine phosphate in muscle, and is usually produced at a fairly constant rate by the body. Creatinine levels in blood and urine may be used to calculate the creatinine clearance (CrCl), which reflects the glomerular filtration rate (GFR), an important clinical index of renal function.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04598516	Withdrawn	Acute Kidney Injury (Nontraumatic)\|Contrast-induced Nephropathy\|Renal Insufficiency	Maastricht University Medical Center	November 1 2097	--
NCT04597892	Withdrawn	Renal Insufficiency\|Acute Kidney Injury\|Contrast-induced Nephropathy	Maastricht University Medical Center	May 1 2097	--
NCT06226662	Not yet recruiting	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	NovelMed Therapeutics	June 2025	Phase 2
NCT05847179	Not yet recruiting	Werner Syndrome	PRG Science & Technology Co. Ltd.	January 1 2025	Phase 2
NCT05935293	Not yet recruiting	Renal Transplantation\|Dexmedetomidine	Eduardo Schiffer\|University Hospital Geneva	December 1 2024	Phase 4

References
https://pubmed.ncbi.nlm.nih.gov/22465051/ https://pubmed.ncbi.nlm.nih.gov/16908915/

References

https://pubmed.ncbi.nlm.nih.gov/22465051/
https://pubmed.ncbi.nlm.nih.gov/16908915/

Chemical Information

Molecular Weight	113.12	Formula	C₄H₇N₃O
CAS No.	60-27-5	SDF	Download Creatinine SDF
Synonyms	NSC13123
Smiles	CN1CC(=O)N=C1N

Storage and Stability

Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
			1 month-20°Cin solvent

In vitro
Batch:

Water : 23 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):